<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03212430</url>
  </required_header>
  <id_info>
    <org_study_id>L-kynurenin H-16033148</org_study_id>
    <nct_id>NCT03212430</nct_id>
  </id_info>
  <brief_title>The Effect of Intravenous L-kynurenine (LKYN) on Cerebral Hemodynamics in Healthy Volunteers</brief_title>
  <official_title>The Effect of Intravenous L-kynurenine (LKYN) on Cerebral Hemodynamics in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To measure the cerebral hemodynamic effect of L-kynurenine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim: To investigate the physiological effect of L-Kynurenine after intravenous administration
      to healthy volunteers.

      Hypothesis: L-kynurenine induces vasodilation in the cerebral vessels and trigger headache in
      healthy individuals.

      Methods: 6 healthy volunteers will receive intravenous infusion of L-kynurenine using the
      following doses 12, 24, and 36 nmol kg-1 min-1 over 20 min on 3 different days with at least
      1 day in between. Before and after infusion (at 20, 40, 60, 80 and 100 min) we will record
      vital signs, circumferences of middle cerebral artery, superficial temporalis artery and
      headache intensity and characteristics.

      The subjects will then have a questionnaire about headache for the following 24 hours.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Pilot, Open label</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Velocity of MCA (VMCA)</measure>
    <time_frame>Change from baseline VMCA at two hours after administration of L-kynurenine</time_frame>
    <description>Measured in MCA (middle cerebral artery) bilaterally with ultrasound (TCD) (2 Mhz, DWL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The diameter of the STA (superficial temporal artery)</measure>
    <time_frame>Change from baseline VMCA at two hours after administration of L-kynurenine</time_frame>
    <description>Measured by high-frequency ultrasound 12 of 29 (Derma Scan C, Cortex Technology, Denmark)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Headache</measure>
    <time_frame>occurrence of headache undtil 24 hours after infusion.</time_frame>
    <description>Headache declared orally on a verbal rating scale (VRS) 0-10. 0 represents no pain and 10 the worst possible headache.</description>
  </primary_outcome>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Headache</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-kynurenine</intervention_name>
    <description>intravenous infusion of L-kynurenine to healthy individuals.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy volunteers of both sexes.

          2. 18-60 years.

          3. 50-90 kg.

          4. Women of childbearing potential must use adequate contraception.

        Exclusion Criteria:

          1. All primary headaches

          2. First-degree relative with migraine

          3. Headache less than 48 hours before the tests start

          4. Daily consumption of drugs of any kind other than oral contraceptives.

          5. Pregnant or nursing women. Cardiovascular disease of any kind, including
             cerebrovascular diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Messoud Ashina, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of neurology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohammad A Al-Karagholi, MD</last_name>
    <phone>00 45 31 19 16 47</phone>
    <email>mahdi.alkaragholi@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Song Gu, MD</last_name>
    <phone>00 45 60 88 77 27</phone>
    <email>song60887727@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet-Glostrup</name>
      <address>
        <city>Glostrup</city>
        <state>Nordre Ringvej 57</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad A Al-Karagholi, MD</last_name>
      <phone>00 45 31 19 16 47</phone>
      <email>mahdi.alkaragholi@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Song Guo, MD, PhD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2017</study_first_submitted>
  <study_first_submitted_qc>July 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <last_update_submitted>July 8, 2017</last_update_submitted>
  <last_update_submitted_qc>July 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Headache Center</investigator_affiliation>
    <investigator_full_name>Mohammad Al-Mahdi Al-Karagholi</investigator_full_name>
    <investigator_title>MD, PhD student, Principal investigator</investigator_title>
  </responsible_party>
  <keyword>L-kynurenine</keyword>
  <keyword>Cerebral hemodynamic</keyword>
  <keyword>Headache</keyword>
  <keyword>Mohammad Al-Mahdi Al-Karagholi</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>1. Using a controlled access approach, using a transparent and robust system to review requests and provide secure data access; 2. seeking consent for sharing IPD from trial participants in all future clinical trials with adequate assurance that patient privacy and confidentiality can be maintained; and 3. Establishing an approach to resource the sharing of IPD which would include support from trial funders, sponsor organisations and users of IPD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

